Abstract:It is notorious that cancer cells alter their metabolism to adjust to harsh environments of hypoxia and nutritional starvation. Metabolic reprogramming most often occurs in the tumor microenvironment (TME). TME is defined as the cellular environment in which the tumor resides. This includes surrounding blood vessels, fibroblasts, immune cells, signaling molecules and the extracellular matrix (ECM). It is increasingly recognized that cancer cells, fibroblasts and immune cells within TME can regulate tumor progression through metabolic reprogramming. As the most significant proportion of cells among all the stromal cells that constitute TME, cancer-associated fibroblasts (CAFs) are closely associated with tumorigenesis and progression. Multitudinous studies have shown that CAFs participate in and promote tumor metabolic reprogramming and exert regulatory effects via the dysregulation of metabolic pathways. Previous studies have demonstrated that curbing the substance exchange between CAFs and tumor cells can dramatically restrain tumor growth. Emerging studies suggest that CAFs within the TME have emerged as important determinants of metabolic reprogramming. Metabolic reprogramming also occurs in the metabolic pattern of immune cells. In the meanwhile, immune cell phenotype and functions are metabolically regulated. Notably, immune cell functions influenced by metabolic programs may ultimately lead to alterations in tumor immunity. Despite the fact that multiple previous researches have been devoted to studying the interplays between different cells in the tumor microenvironment, the complicated relationship between CAFs and immune cells and implications of metabolic reprogramming remains unknown and requires further investigation. In this review, we discuss our current comprehension of metabolic reprogramming of CAFs and immune cells (mainly glucose, amino acid, and lipid metabolism) and crosstalk between them that induces immune responses, and we also highlight their contributions to tumorigenesis and progression. Furthermore, we underscore potential therapeutic opportunities arising from metabolism dysregulation and metabolic crosstalk, focusing on strategies targeting CAFs and immune cell metabolic crosstalk in cancer immunotherapy.

Editorial: Tumor microenvironment and metabolic reprogramming in cancer

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy

Emerging Landscapes of Tumor Immunity and Metabolism

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

The cancer metabolic reprogramming and immune response

Metabolic Manipulation of the Tumour Immune Microenvironment

Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution

Metabolic interventions: A new insight into the cancer immunotherapy

The Role of Tumor Metabolic Reprogramming in Tumor Immunity

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy